176 related articles for article (PubMed ID: 21108850)
1. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
Habl G; Jensen AD; Potthoff K; Uhl M; Hof H; Hajda J; Simon C; Debus J; Krempien R; Münter MW
BMC Cancer; 2010 Nov; 10():651. PubMed ID: 21108850
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
Jensen AD; Krauss J; Potthoff K; Desta A; Habl G; Mavtratzas A; Windemuth-Kiesselbach C; Debus J; Münter MW
BMC Cancer; 2011 May; 11():182. PubMed ID: 21595970
[TBL] [Abstract][Full Text] [Related]
3. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
[TBL] [Abstract][Full Text] [Related]
5. Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
Jensen AD; Krauss J; Potthoff K; Simon C; Nikoghosyan AV; Lossner K; Debus J; Münter MW
Radiat Oncol; 2012 Apr; 7():57. PubMed ID: 22472064
[TBL] [Abstract][Full Text] [Related]
6. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
Zwicker F; Roeder F; Thieke C; Timke C; Münter MW; Huber PE; Debus J
Strahlenther Onkol; 2011 Jan; 187(1):32-8. PubMed ID: 21234529
[TBL] [Abstract][Full Text] [Related]
7. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
[TBL] [Abstract][Full Text] [Related]
8. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
[TBL] [Abstract][Full Text] [Related]
9. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
[TBL] [Abstract][Full Text] [Related]
12. [Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Zhang X; Wang J; Wu W; Ma L; Liu M; Zhao F; Huang D
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jul; 49(7):558-63. PubMed ID: 25257270
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
Shapiro LQ; Sherman EJ; Riaz N; Setton J; Koutcher L; Zhang Z; Shi W; Fury MG; Wolden SL; Pfister DG; Morris L; Lee N
Oral Oncol; 2014 Oct; 50(10):947-55. PubMed ID: 25132089
[TBL] [Abstract][Full Text] [Related]
14. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
Tong CC; Lau KH; Rivera M; Cannan D; Aguirre-Ghiso J; Sikora AG; Gupta V; Forsythe K; Ko EC; Misiukiewicz K; Gurudutt V; Teng MS; Packer SH; Genden EM; Kao J
Oncol Rep; 2012 May; 27(5):1580-6. PubMed ID: 22322320
[TBL] [Abstract][Full Text] [Related]
16. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Staar S; Rudat V; Stuetzer H; Dietz A; Volling P; Schroeder M; Flentje M; Eckel HE; Mueller RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1161-71. PubMed ID: 11483325
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
[TBL] [Abstract][Full Text] [Related]
18. Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.
Semrau R; Temming S; Preuss SF; Klubmann JP; Guntinas-Lichius O; Müller RP
Strahlenther Onkol; 2011 Oct; 187(10):645-50. PubMed ID: 21947123
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
[TBL] [Abstract][Full Text] [Related]
20. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C
Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
